← SynDRA
JNJ-38877605
SynDRA canonical compound SYN0033783 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | Tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- tyrosine kinase inhibitor
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NQO2
- PIP4K2C
- PIM1
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- NUAK2
- NTRK1
- PHKG2
- AAK1
- NLK
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2A
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIM2
- NEK9
- ABL1
- NEK7
- MAPK9
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- JNJ-38877605-AAA
- C-met inhibitor, Ortho Biotech Oncology Research & Development
- C-met inhibitor (solid tumors), ORD/J&J PRD
- JNJ 38877605
- RefChem:1073731
- UNII-15UDG410PN
- C19H13F2N7
- MFCD11977274
- MLS006010960
- SCHEMBL182199
- orb1301078
- SCHEMBL29358742
- SCHEMBL30028214
- CHEBI:91417
- BDBM163243
- GLXC-90142
- HMS3244G09
- HMS3244G10
- HMS3244H09
- HMS3295K11
- HMS3654M04
- HMS3750I11
- EX-A2081
- EBC-11437
- NSC759095
- NSC800776
- s1114
- AKOS015896605
- CCG-264826
- NSC-759095
- NSC-800776
- SB16606
- SDCCGSBI-0654345.P001
- NCGC00263189-01
- NCGC00263189-02
- NCGC00263189-05
- NCGC00263189-06
- AC-27418
Look up JNJ-38877605 in the interactive SynDRA portal →